Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings

Syros Pharmaceuticals Inc SYRS announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609.
Updated data demonstrated clinical activity in heavily pre-treated patients across multiple tumor settings.
The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.
Thirteen patients (28.9%) achieved stable disease (SD), with six patients' tumor regressions of up to 20% across multiple tumor types.
The most substantial clinical activity was observed in heavily pre-treated patients with advanced pancreatic cancer.
Five of 13 (38.5%) evaluable patients achieved SD, with tumor reductions in two patients.
Reductions in the CA 19-9 tumor marker were observed in three of four pancreatic cancer patients. These reductions ranged from 32% to 72%.
One metastatic pancreatic cancer patient who had failed two prior lines of therapy and relapsed after the third line of treatment, experienced prolonged SD of up to 10 months.
Syros plans to initiate an expansion cohort evaluating SY-5609 in combination with chemotherapy for pancreatic cancer in Q4 of 2021.
The Company also plans to initiate a Phase 1b trial evaluating SY-5609 in combination with Bruton's tyrosine kinase (BTK) inhibitor for mantle cell lymphoma in 1H of 2022 the first half of 2022.
Price Action: SYRS stock is down 2.36% at $4.96 during the market session on the last check Monday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga